Impact of pain associated with the subcutaneous administration of adalimumab.
Adalimumab
/ administration & dosage
Adult
Anti-Inflammatory Agents
/ administration & dosage
Anxiety
/ etiology
Drug Compounding
Female
Humans
Inflammatory Bowel Diseases
/ drug therapy
Injections, Subcutaneous
/ adverse effects
Male
Medication Adherence
/ statistics & numerical data
Middle Aged
Pain Perception
/ physiology
Pain, Procedural
/ etiology
Self Administration
/ adverse effects
Surveys and Questionnaires
Adalimumab
Adherence
Adherencia
Citrate
Citrato
Dolor
Pain
Subcutaneous
Subcutáneo
Journal
Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
21
03
2019
revised:
01
05
2019
accepted:
14
06
2019
pubmed:
8
9
2019
medline:
31
10
2020
entrez:
8
9
2019
Statut:
ppublish
Résumé
There is limited information regarding the impact of patients' perception of injection pain on adherence to treatments, specifically in inflammatory bowel disease (IBD) patients. Therefore, we aimed to determine the impact of the pain associated with the subcutaneous administration of adalimumab in patients with IBD treated with the old formulation and the new low-volume/citrate-free formulation. A specifically-designed questionnaire was completed by 76 patients with IBD, who started treatment with adalimumab before the availability of the low-volume/citrate-free formulation and were switched to this new formulation. Intensity of pain was measured by using visual analog scales (VAS). A total of 62 patients (82%) experienced injection-related pain with the initial formulation. The perception of pain was associated with a decreased adherence to the treatment (37%), an increase in pre-administration anxiety (25%) or, as a consequence, the patient required someone else to carry out the injection (21%). Younger age was the only factor associated with pain perception. After switching to the new formulation, perception of pain persisted only in 2 patients (3%). Among those who felt pain with the initial formulation, pre-administration anxiety disappeared in 44%; 32% and 42% stated that the new formulation eased adherence and self-administration. The perception of pain related to the subcutaneous administration of therapy negatively impacts on treatment adherence in IBD patients. Improved formulations for subcutaneous administration of drugs can positively impact patients' convenience and adherence.
Sections du résumé
BACKGROUND
BACKGROUND
There is limited information regarding the impact of patients' perception of injection pain on adherence to treatments, specifically in inflammatory bowel disease (IBD) patients. Therefore, we aimed to determine the impact of the pain associated with the subcutaneous administration of adalimumab in patients with IBD treated with the old formulation and the new low-volume/citrate-free formulation.
METHODS
METHODS
A specifically-designed questionnaire was completed by 76 patients with IBD, who started treatment with adalimumab before the availability of the low-volume/citrate-free formulation and were switched to this new formulation. Intensity of pain was measured by using visual analog scales (VAS).
RESULTS
RESULTS
A total of 62 patients (82%) experienced injection-related pain with the initial formulation. The perception of pain was associated with a decreased adherence to the treatment (37%), an increase in pre-administration anxiety (25%) or, as a consequence, the patient required someone else to carry out the injection (21%). Younger age was the only factor associated with pain perception. After switching to the new formulation, perception of pain persisted only in 2 patients (3%). Among those who felt pain with the initial formulation, pre-administration anxiety disappeared in 44%; 32% and 42% stated that the new formulation eased adherence and self-administration.
CONCLUSIONS
CONCLUSIONS
The perception of pain related to the subcutaneous administration of therapy negatively impacts on treatment adherence in IBD patients. Improved formulations for subcutaneous administration of drugs can positively impact patients' convenience and adherence.
Identifiants
pubmed: 31492425
pii: S0210-5705(19)30175-X
doi: 10.1016/j.gastrohep.2019.06.008
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Adalimumab
FYS6T7F842
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
9-13Informations de copyright
Copyright © 2019 Elsevier España, S.L.U. All rights reserved.